Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This protocol will investigate the effectiveness of plerixafor in the up-front setting in avoiding a second round of mobilization and whether this translates into a clinical and economic benefit.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Treatments: JM 3100; Lenograstim; Plerixafor

Criteria

Inclusion Criteria:

• Patients with multiple myeloma or non-Hodgkin's lymphoma with a planned autologous transplant and who are eligible for peripheral stem cell mobilization.

• Karnofsky Performance Status ≥ 70.

• Age ≥ 18

• Less than 30% involvement of marrow with disease.

Exclusion Criteria:

• > 30% marrow involvement with disease

• Age < 18.

• Pregnant women.